STELLUX® Chemi Active GLP-1 (7-36) amide ELISA

STELLUX® Chemi Active GLP-1 (7-36) amide ELISA
$495.00
  • Buy 5 for $470.00 each and save 6%
  • Buy 9 for $445.00 each and save 11%
  • Buy 13 for $420.00 each and save 16%
  • Buy 16 for $396.00 each and save 20%

The STELLUX® Chemi Active GLP-1 (7-36) amide ELISA is intended for the quantitative determination of active GLP- 1 (7-36) amide in human, mouse, and rat EDTA plasma samples collected in the presence of DPP-4 inhibitor.



  • Sample Volume: 25 µL

  • Analytical Sensitivity: 0.15 pM

  • Functional Sensitivity: 0.45 pM 

  • Specificity: 100% for GLP-1 (7-36 amide); Non-detect for other forms

Availability: In stock

Request a Quote
OR
$349 special introductory pricing now through August 31, 2018.
Catalog Number
80-GLP1A-CH01
Quote Request

Product: STELLUX® Chemi Active GLP-1 (7-36) amide ELISA

Catalog#: 80-GLP1A-CH01


Billing Address


Shipping Address

Same as Billing Address
Specifications
Specifications

Additional Information

Catalog #
80-GLP1A-CH01
Species
Human, Mouse, Rat
Regulatory Status
Research Use Only. Not for Use in Diagnostic Procedures.
Product Distribution
Available Worldwide
Range
0.45 - 151.6 pM (1.5 - 500 pg/mL)
Sensitivity
0.15 pM (0.49 pg/mL)
Sizes
96 Wells
Sample Types
EDTA Plasma
Incubation Time
2 hr
Incubation Time
2 hr 52 min
Sample Size
25 µL
Instructions for Use
Safety Data Sheet
Additional Information
Additional Information

Glucagon-like peptide-1 (GLP-1) is an extensively well-characterized incretin hormone which regulates both insulin and glucagon secretion. GLP-1 is a highly sought after therapeutic target due to its beneficial effects on glucose homeostasis, particularly through regulation of beta cell mass, function, and viability. GLP-1 is produced in intestinal L-cells in response to food and is well conserved across species. GLP-1 is derived from the cleavage of proglucagon to generate a 1-37 amino acid peptide. Fasting reduces circulating levels of GLP-1. GLP-1 has many physiological effects on the body. Diabetes and obesity scientists have been using two main  GLP-1 research approaches: DPP-4 inhibition and GLP-1 analogs. DPP-4 can inactivate GLP-1 to its forms of GLP-1 (9-36 amide) and GLP-1 (9-37). By inhibiting DPP-4, scientists hope that GLP-1 can continue to influence insulin secretion and restore balance to energy homeostasis. The goal of developing GLP-1 analogs is to engineer a better GLP-1 molecule that has a longer half-life, thus providing longer influences over insulin secretion.

Product Reviews
Product Reviews

Write a Review

Only registered users can write reviews. Please, log in or register